Temozolomide magnetic temperature-sensitive liposome and preparation method thereof

Abstract

The invention discloses a temozolomide magnetic temperature-sensitive liposome and relates to the field of nanomedicine. Firstly, a solid precursor liposome is prepared from a small molecular drug temozolomide (TMZ) and a liposome with a phase transition temperature, and then hydration is carried out by using an ultra-small ferroferric oxide magnetic nanoparticle (Fe3O4 MNPs) suspension to form atemozolomide magnetic temperature-sensitive liposome (TMZ / Fe-TSL). The drug delivery mode of the form combines magnetofluid thermal therapy, chemotherapy and temperature-controlled drug release, so that the plasma half-life period of the temozolomide is prolonged, the curative effect of the temozolomide is enhanced, and the drug toxicity can be reduced. A temozolomide magnetic temperature-sensitive liposome drug delivery system disclosed by the invention provides a wide transformation and application prospect for magnetofluid thermal therapy combined with chemotherapy, and also provides a newscheme for treatment and research of brain glioma.

Description

technical field [0001] The invention relates to the field of nanomedicine, in particular to a temozolomide magnetic temperature-sensitive liposome and a preparation method thereof. Background technique [0002] Brain tumors are a diverse group of neoplasms that originate in different cells of the central nervous system, and although rare, their incidence has been increasing over the past 50 years. According to statistics from the American Brain Tumor Registry, the incidence of primary brain and nervous system tumors in adults is about 27.9 / 100,000. Glioma accounts for about 40% of primary brain tumors, with an adult incidence rate of 6 / 100,000 and a 5-year survival rate of 20-30%. At present, surgery is the first choice for the treatment of gliomas. However, because gliomas mostly grow infiltratingly and have unclear boundaries with normal brain tissue, it is difficult to completely remove them by surgery, and recurrences often occur after surgery. As adjuvant therapy, che...

AI Technical Summary

Problems solved by technology

Although temozolomide has the advantages of oral administration and low toxicity, it is eliminated rapidly in the body, and its half-life in plasma is only 1.8h. To achieve effective drug concentration in cerebrospinal fluid, continuous high-dose administration is required

Images